| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Mar 4, 2020 | EBS Emergent Biosolutions Inc. | Zoon Kathryn C62 | Director | Sell | 991 | $60.65 | $60,103.46 | -5.7% | |
| Mar 4, 2020 | TEVA Teva Pharmaceutical Industries Ltd | Griffin Deborah A | Chief Accounting Officer | Sell | 4,807 | $11.23 | $53,979.73 | -100% | |
| Mar 4, 2020 | ANIP Ani Pharmaceuticals Inc | Haughey Thomas | Director | Buy | 5,000 | $45.10 | $225,510.00 | +34.3% | |
| Mar 4, 2020 | ZTS Zoetis Inc. | Alaix Juan Ramon | Director | Sell | 263,660 | $141.26 | $37,243,510.65 | -25.1% | |
| Mar 4, 2020 | AMRX Amneal Pharmaceuticals, Inc. | Patel Chirag K. | President, Co-ceo &Director | Buy | 250,000 | $3.90 | $974,958.01 | +102.4% | |
| Mar 4, 2020 | AMRX Amneal Pharmaceuticals, Inc. | Patel Chintu | Co-ceo And Director | Buy | 250,000 | $3.90 | $974,941.89 | +102.4% | |
| Mar 3, 2020 | TEVA Teva Pharmaceutical Industries Ltd | O'Grady Brendan P. | EVP, North America Commercial | Sell | 463 | $11.37 | $5,262.37 | -3.2% | |
| Mar 3, 2020 | TEVA Teva Pharmaceutical Industries Ltd | Daniell Richard | Exec. VP, European Commercial | Sell | 991 | $11.77 | $11,659.81 | -9.3% | |
| Mar 3, 2020 | TEVA Teva Pharmaceutical Industries Ltd | Nazzi Gianfranco | EVP, International Markets | Sell | 548 | $11.77 | $6,447.60 | -2.8% | |
| Mar 3, 2020 | AMRX Amneal Pharmaceuticals, Inc. | Patel Gautam | Director, 10% Owner | Buy | 150,000 | $3.93 | $589,073.34 | +338.4% | |
| Mar 3, 2020 | TEVA Teva Pharmaceutical Industries Ltd | Griffin Deborah A | Chief Accounting Officer | Sell | 4,107 | $11.53 | $47,364.89 | -100% | |
| Mar 2, 2020 | ZTS Zoetis Inc. | Chen Heidi C.47 | Executive Vice President | Sell | 1,179 | $134.30 | $158,339.70 | -6.7% | |
| Mar 2, 2020 | BMY Bristol Myers Squibb Co | Vessey Rupert53 | Pres., Research &Early Dev. | Sell | 84,308 | $60.59 | $5,108,221.72 | -63.6% | |
| Mar 2, 2020 | LLY Eli Lilly & Co | Zakrowski Donald A | Chief Accounting Officer | Sell | 3,700 | $128.00 | $473,600.00 | -43.8% | |
| Mar 2, 2020 | AMPH Amphastar Pharmaceuticals, Inc. | Petersen Floyd F.51 | Director | Sell | 500 | $15.56 | $7,781.75 | -0.7% | |
| Mar 2, 2020 | ELAN Elanco Animal Health Inc | Hoover R David50 | Director | Buy | 8,000 | $27.19 | $217,519.00 | +18.1% | |
| Feb 28, 2020 | AKBA Akebia Therapeutics, Inc. | Tubridy Karen L | SVP, Chief Development Officer | Sell | 3,454 | $8.70 | $30,049.80 | -3.9% | |
| Feb 28, 2020 | AKBA Akebia Therapeutics, Inc. | Hadas Nicole R.60 | SVP, Chief Legal Officer | Sell | 7,050 | $8.70 | $61,335.00 | -3.2% | |
| Feb 28, 2020 | ESPR Esperion Therapeutics, Inc. | Mayleben Timothy M | President &CEO | Buy | 5,000 | $49.00 | $245,000.00 | +4.8% | |
| Feb 28, 2020 | AMRX Amneal Pharmaceuticals, Inc. | Todisco Joseph76 | SVP, Specialty Commercial | Buy | 40,000 | $3.62 | $144,800.00 | +19.3% | |
| Feb 28, 2020 | AKBA Akebia Therapeutics, Inc. | Dahan Michel59 | SVP, Chief Operating Officer | Sell | 6,972 | $8.70 | $60,656.40 | -3.3% | |
| Feb 28, 2020 | AKBA Akebia Therapeutics, Inc. | Amello Jason | SVP, CFO &Treasurer | Sell | 6,976 | $8.70 | $60,691.20 | -4.6% | |
| Feb 28, 2020 | LNTH Lantheus Holdings, Inc. | Marshall Robert J. Jr.53 | CFO And Treasurer | Sell | 2,435 | $15.66 | $38,137.31 | -2.3% | |
| Feb 27, 2020 | LNTH Lantheus Holdings, Inc. | Leno Sam R | Director | Sell | 2,700 | $15.85 | $42,792.30 | -7.1% | |
| Feb 27, 2020 | EBS Emergent Biosolutions Inc. | Bailey Sue | Director | Sell | 6,572 | $56.93 | $374,132.13 | -14.2% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.